US 12,239,654 B2
Compounds and methods for treating neurological and cardiovascular conditions
William S. Korinek, Mystic, CT (US); James D. Lechleiter, San Antonio, TX (US); Theodore E. Liston, Stonington, CT (US); and Kenneth A. Jacobson, Silver Spring, MD (US)
Assigned to Astrocyte Pharmaceuticals, Inc., Cambridge, MA (US); Board of Regents, The University of Texas System, Austin, TX (US); and The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Appl. No. 16/095,282
Filed by Astrocyte Pharmaceuticals, Inc., Cambridge, MA (US); Board of Regents, the University of Texas System, Austin, TX (US); and The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
PCT Filed Apr. 21, 2017, PCT No. PCT/US2017/028996
§ 371(c)(1), (2) Date Oct. 19, 2018,
PCT Pub. No. WO2017/185061, PCT Pub. Date Oct. 26, 2017.
Claims priority of provisional application 62/325,860, filed on Apr. 21, 2016.
Prior Publication US 2022/0305044 A1, Sep. 29, 2022
Int. Cl. A61K 31/7076 (2006.01); A61K 31/52 (2006.01); A61P 25/00 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 31/52 (2013.01); A61P 25/00 (2018.01)] 11 Claims
 
1. A method of treating an injury, disease, or condition selected from traumatic brain injury (TBI) and a stroke selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, and transient ischemic attacks (TIA), comprising administering to a patient in need thereof an effective amount of a compound selected from:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.